Pre-surgery chemotherapy with abemaciclib for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding a targeted therapy (abemaciclib) to standard chemotherapy before surgery can shrink tumors and improve outcomes in hormone-positive, HER2-negative early breast cancer. It also uses a genetic test (Oncotype DX) to help guide surgical choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have early-stage breast cancer (stage II to IIIB) that is hormone-receptor positive and HER2-negative.
- Your doctor recommends chemotherapy before surgery, and you are not a candidate for upfront breast-conserving surgery or have involved lymph nodes.
- You are able to swallow medications and are willing to undergo breast surgery after the pre-surgery treatment.
- You have adequate blood counts, kidney, and liver function as determined by standard tests.
- If you are of childbearing age, you must have a negative pregnancy test and agree to use effective non-hormonal contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral medications (abemaciclib and giredestrant) given before surgery to women with a common type of early breast cancer (hormone receptor-positive, HER2-negative). The goal is to see if this treatment can shrink the tumor before surgery.
This trial combines a short course of radiation before surgery with two oral medications (abemaciclib and letrozole) to treat early-stage, hormone-sensitive breast cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
This trial tests a drug called abemaciclib for people with early-stage, hormone-receptor-positive, HER2-negative breast cancer who still have cancer DNA in their blood after completing standard treatment. It aims to see if taking this drug can reduce the chance of cancer coming back.
This study tests whether women with early-stage HR+/HER2- breast cancer can safely take a higher dose of the drug abemaciclib (Verzenio) after surgery. The goal is to keep the treatment as strong as possible while managing side effects.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.